Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

13:30 BST Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials...


13:00 BST Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as...


07:30 BST Elthera Awarded 2.5 M €Grant From Horizon 2020 Program

Elthera is pleased to announce that it has been awarded 2.5 M € through the Horizon 2020 programme. Horizon 2020 is the financial instrument...


16 Jun, 2019, 15:09 BST New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial....


14 Jun, 2019, 11:40 BST BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy

BerGenBio ASA (OSE:BGBIO) today presents data showing significant efficacy in a Phase II clinical trial (BGBC003, NCT02488408) evaluating...


14 Jun, 2019, 09:20 BST New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in...


13 Jun, 2019, 12:30 BST Updates on Development of AMO Pharma's AMO-02 Presented at International Myotonic Dystrophy Consortium Meeting

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited...


13 Jun, 2019, 12:30 BST GT BIOPHARMA GTB-1550 Multi-Targeted Bispecific Drug Conjugate Strategically Positioned in New Class of ADC Drugs

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company developing GTB-1550, a novel multi-target bispecific drug conjugate therapy for ...


12 Jun, 2019, 13:38 BST CartiHeal Enrolls the 200th Patient in Its Pivotal Clinical Study in San Diego, CA

CartiHeal, developer of the Agili-C™ implant for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints, successfully...


12 Jun, 2019, 12:00 BST Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the monotherapy expansion stage of its ARTISTRY-1 clinical trial to evaluate the...


11 Jun, 2019, 11:00 BST 29th EWMA Conference: Latest Clinical Data on Nexodyn® AOS Demonstrating Higher Healing Performance in Chronic Leg Ulcers Presented by Applied Pharma Research

APR Applied Pharma Research sa (APR) presented at the recent 29th conference of the European Wound Management Association (EWMA) in Göteborg, the...


11 Jun, 2019, 09:00 BST New Study Shows Rifaximin Significantly Reduced the Number and Length of Hospitalisations in Patients With Overt Hepatic Encephalopathy (HE) Awaiting Liver Transplatation

Rifaximin significantly reduced the incidence of all-cause hospital admissions in HE patients with advanced cirrhosis on the waiting list for liver...


11 Jun, 2019, 06:00 BST Pharming Announces Initiation of Clinical Phase I/II Pre-Eclampsia Study

Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) today announces that, following receipt of the Dutch investigating...


10 Jun, 2019, 16:11 BST Orion Biotechnology Announces Receipt of Pre-IND Guidance From the United States FDA on the Further Development of OB-002O as a Potential Treatment for Solid Tumours

Orion Biotechnology Canada Ltd., today announced that it has received feedback from the Food and Drug Administration (FDA) on a Pre-Investigational...


10 Jun, 2019, 13:05 BST First patients successfully treated in the Nuvaira AIRFLOW-3 COPD pivotal trial

Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, announced the first treatments in the AIRFLOW-3 pivotal trial, ...


10 Jun, 2019, 12:30 BST GT Biopharma Company Update

GT Biopharma, Inc. (OTCQB: GTBP) (OTCQB: GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK...


10 Jun, 2019, 12:06 BST Proton Partners International: Protons to Play a Vital Role in the Battle Against Prostate Cancer

An upsurge in demand for proton beam therapy was predicted today as the centenary of the discovery of the proton was celebrated at a major scientific ...


10 Jun, 2019, 10:27 BST New Research Could Help Predict Seizures Before They Happen

A new study has found a pattern of molecules that appear in the blood before a seizure happens. This discovery may lead to the development of an...


10 Jun, 2019, 08:00 BST Menarini Ricerche at the 24ᵗʰ EHA Congress Presenting the First In Human Clinical Study of SEL24/MEN1703

Menarini Ricerche will present at the 24th EHA Congress 2019 in Amsterdam on the First In Human clinical trial of SEL24/MEN1703 (DIAMOND-01,...


10 Jun, 2019, 08:00 BST Sosei Heptares to Receive New $3 Million Milestone Payment from Pfizer, as It Advances a Second Candidate from the GPCR Collaboration for Clinical Development

Sosei Group Corporation ("the Company"); (TSE: 4565) and its strategic alliance partner Pfizer announce that a new clinical candidate from their...


06 Jun, 2019, 08:00 BST Spectrum Therapeutics Provides Update on Its Global Clinical Research Program and Unveils Pharmacovigilance

Spectrum Therapeutics ("Spectrum"), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the "Company" or "Canopy Growth") is...


06 Jun, 2019, 06:16 BST Nordic Nanovector to Present Preclinical Studies With 212Pb-NNV003, a Novel CD37-specific Targeted Alpha Therapy for CLL and NHL, at TRP 2019

Nordic Nanovector ASA (OSE: NANO) announces that its Chief Scientific Officer, Jostein Dahle, will present results from preclinical studies with...


05 Jun, 2019, 08:00 BST Launch of CIEMAR, the Largest Data Collection on Microwave Ablation in Patients With Liver Metastatic Disease

This European-wide observational study on the treatment of liver-only or liver-dominant metastatic disease in patients with colorectal adenocarcinoma ...


05 Jun, 2019, 08:00 BST Vaccitech Universal Flu Vaccine Passes Phase 2b Clinical Development Milestones

Vaccitech Ltd. announces that it has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100) to the first participants in a Flu...


04 Jun, 2019, 11:49 BST mAPPing the New World of Allergy at EAACI Annual Congress 2019

The European Academy for Allergy and Clinical Immunology (EAACI) Annual Congress presents new avenues for controlling allergic rhinitis and asthma by ...